News & Events

Nov 2015

Dr Talia Golan - Sheba hospital at AACR

Dr Talia Golan from Sheba hospital will present the results of the dose escalation (part of Efranat's study)  at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, at Boston on November 7th, 2015. 

read more read more Download PDF
Oct 2015

Second expanded cohort of Phase I study

Efranat Ltd, a clinical –stage bio-pharmaceutical company focuses on the development and commercialization of EF-022, an immune modulating reagent, for the treatment of cancer and chronic infectious diseases,  announced today that Dr. Talia Golan , Sheba medical Center, Israel, has received final regulatory approval to commence the second part, the expansion cohort, of EF-022 Phase I study in advanced solid malignancies.

 Uri Yogev, Chief Executive Officer of Efranat, stated, "we are extremely pleased that our promising therapeutic candidate is approved to commence the second expanded cohort of the Phase I study of EF-022 in solid tumors. This study is an open label single-center phase I study in patients diagnosed with inoperable, recurrent or metastatic malignant solid tumors, deemed incurable, and who have failed to respond to standard therapy or for whom no standard therapy is available.

 

 

read more read more Download PDF
Sept 2015

Dr. Rinat Rotem joined Efranat

We are very pleased to announce that Dr. Rinat Rotem – Yehudar had joined Efranat as EVP Research & Development

read more read more Download PDF
Aug 2015

Efranat's product name was changed

Efranat's product name was changed to EF-022 

read more read more Download PDF
June 2015

Phase I Dose Escalation completion

Phase I Dose Escalation in 12 patients with solid tumors has been successfully completed with promising results
MTD has not been reached. Treatment was well-tolerated with only mild adverse effects mainly flu like symptoms and rash.
Interesting pharmacodynamics findings were observed and will be further investigated in the next part of the study.
The Dose Expansion part of the study will begin on August 2015 and will include additional 24 patients. 

read more read more Download PDF
Aug 2014

Mr. Oliver Curme joined Efranat's BOD

We are very pleased to announce that Mr.Oliver Curme joined Efranat as member of its board of directors.

read more read more Download PDF
Aug 2014

Mr. Yuval Yanai joined Efranat's BOD

Mr. Yuval Yanai joined Efranat's BOD

We are very pleased to announce that Mr.Yuval Yanai joined Efranat as member of its board of directors. Mr Yanai brings a wide knowledge and experience from the Bio -Pharma, medical devise and High tech industry. Mr Yanai will be a great contribution to our company and team. 

read more read more Download PDF
May 2014

Phase 1 clinical trial initiated

Efranat initiates Phase 1 clinical trial at "Sheba" hospital in Israel.

Enter "Clinical trials web site" 

read more read more Download PDF
March 2014

Israel's Ministry of Health approval

Israel's Ministry of Health approved phase 1 clinical trial in cancer patients with advanced solid tumors to be conducted at the Israeli Sheba Hospital.

read more read more Download PDF
Dec 2013

Sheba hospital IRB approval

The Ethics Committee Review Board of the Sheba Hospital, Israel approved the layout of the phase 1 clinical trial of EF-022 treatment, in cancer patients with advanced solid tumors.

read more read more Download PDF
Oct 2013

Efranat completed GMP production

Efranat has successfully completed production of GMP batches designed for the first phase of the clinical trial. Batches have successfully passed a series of released tests and  will be used in the clinical trial in 2014.

read more read more Download PDF
Aug 2013

Dr. David Sidransky joined Efranat's Board of Directors.

We are very pleased to announce that Dr.David Sidransky joined Efranat as member of its board of directors. Dr. Sidransky’s knowledge and impressive experience as a world renowned oncologist and research scientist will be a great contribution to our company and team. 

read more read more Download PDF
Nov. 2012

Production Agreement with Kamada

Efranat and Kamada signed a production agreement allowing Efranat to produce EF-022 in the cGMP-compliant, FDA-approved, advanced production facilities of Kamada.

 

read more read more Download PDF
Mar. 2012

Efranat Moves to New Expanded Facility

Efranat moved to its new facility in Rehovot Science Park, adjacent to the esteemed Weizmann Institute of Science.

read more read more Download PDF
Nov. 2011

Round of Investment

Efranat has signed an investment agreement with a group of investors led by Dr. Shmuel Cabilly.

read more read more Download PDF
Oct. 2010

Successful Canine Treatment

Exciting results obtained from compassionate treatment on Canines with advanced spontaneous tumors, in collaboration with canine oncologist, Dr. Gillian Dunk of the Koret School of Veterinary Medicine in Israel.

read more read more Download PDF
Back Up

News & Events

News & Events
  • Nov 2015

    Dr Talia Golan - Sheba hospital at AACR

    read more
  • Oct 2015

    Second expanded cohort of Phase I study

    read more
  • Sept 2015

    Dr. Rinat Rotem joined Efranat

    read more
  • Aug 2015

    Efranat's product name was changed

    read more
  • June 2015

    Phase I Dose Escalation completion

    read more